LBL-015

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameLBL-015
Drug Alias NameLBL-015
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionTransforming growth factor beta inhibitorsProgrammed cell death protein 1 blockers
TargetsTransforming growth factor betaProgrammed cell death protein 1
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesNanjing Leadsbiolabs Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesNanjing Leadsbiolabs Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A